Small Cap Feast
Small Cap Feast – 23 October 2019
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 876
Total number of AIM Companies trading: *
* As at 20 October 2019
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): *
Total number of NEX Growth Market Companies trading: *
* As at 20 October 2019
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): *
Total number of Standard List Companies trading: *
* As at 20 October 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
Off the Menu:
What’s Cooking in the IPO Kitchen?
Main Market premium
African Export-Import Bank a supranational financial institution whose purpose is to facilitate, promote and expand intra- and extra- African trade, of its potential intention to publish a registration document, the Bank hereby confirms its intention to proceed with an Initial Public Offering. The GDRs are expected to be admitted to the standard listing segment of the Official List of the FCA and to trading on the Main Market of the LSE.
DNEG Limited intends to apply for admission of its Shares to the premium listing segment of the Official List of the FCA and to trading on the London Stock Exchange’s main market for listed securities. The Offer will be comprised of new Shares to be issued by the Company (to raise expected gross proceeds of £150m). Admission is expected to take place in November 2019.
Crossword Cybersec*(CCS) 460p £21.5m
Crossword Cybersecurity announced that Chief Product Officer, Jake Holloway, will be speaking at the CIPS UK Conference 2019 (the leading procurement conference in the UK,) on the importance of every organisation implementing a Supplier Assurance Framework. Jake’s talk will cover this in the context of a case study on Rizikon Assurance, the Company’s supplier assurance management portal. Crossword Cybersecurity plc is proud to sponsor the event.
Crossword’s flagship product, Rizikon Assurance, helps companies to gain visibility on the risks posed by third party suppliers.
Over 100 procurement senior managers are currently evaluating Rizikon Assurance for use in their enterprise, and a growing list of Rizikon Assurance users are quickly realising the benefits of a centralised approach to third party risk
DXS International* (DXSP) 6p £2.1m
DXS International, the healthcare information and digital clinical decision support systems provider, announces that it has been awarded a place on the new NHS GPIT Futures framework. This framework, beginning on the 1st January 2020, will enable GP Practices to purchase DXS products and services funded centrally by the NHS rather than from their own practice funds.
This GPIT Futures award follows an evaluation of a tender to The Health & Social Care Information Centre (known as NHS Digital).
GPIT Futures replaces the current GPSoC2 framework, where DXS is currently an accredited Supplier of Clinical Decision Support to UK Primary Care, and where our Core Solution, DXS Point of Care is currently centrally funded by the NHS. All approved products and services will be placed on the NHS Digital Online Buying Catalogue that will make it easy for GP Practices to purchase DXS products and services.
Yu Group (YU.) 82.5p £13.3m
Yü Group PLC, the independent supplier of utilities to the UK corporate sector, welcomes the consultation, launched 22 October 2019, of Ofgem’s supplier licencing review.
The Group supports the underlying themes of promoting more responsible risk management, with enhanced internal governance and increased oversight. The Board fully embrace these principles and is confident that the Group is already well positioned to meet these objectives.
The Group’s risk management practices in relation to its industry obligations are robust and embedded in the organisation. The Group has continued to meet its ongoing commitments to Ofgem. Contrary to reports of some suppliers’ late payments, the Board is pleased to confirm that Yü Group made full payment, when due, of its obligations under the Government’s Renewables Obligation scheme.
Panthera Resources (PAT) 8p £7.33m
Panthera Resources, the gold exploration and development company with assets in India and West Africa, provides an update on the Court case pending with the Rajasthan High Court and the recently announced financing agreement with Republic Investment Management.
MMI’s case on behalf of the Joint Venture was not heard on Friday 18 October 2019 as anticipated and was rescheduled for 22 October 2019. However, it was listed at number 221 and the Court failed to process the case, again as a result of staffing shortages. We await confirmation of a new date for the hearing and will advise the market accordingly.
Additionally, we have been advised by Republic Investment Management that the final £100k tranche of the recently announced £500k financing has been authorised for transfer to Panthera’s account. Upon receipt of those funds we will advise the market regarding settlement details.
Itaconix (ITX) 1.55p £4.17m
Itaconix, a leading innovator in sustainable specialty polymers, is today introducing its new VELAFRESH™ odour control product line for personal care at the Sepawa Home and Personal Care Conference in Berlin.
Itaconix is building the VELAFRESH™ brand with current and new products to meet emerging customer needs and expand the revenue opportunities for its proprietary odour neutralisation technology:
the Company is launching its new VELAFRESH™ ZP30 product to add further formulating and cost advantages in certain personal care applications, and
the Company is rebranding its current odour control product, RevCare™ MC, as VELAFRESH™ ZP20.
Nexus Infrastructure (NEXS) 140p £50.7m
Nexus Infrastructure, a leading provider of essential infrastructure services to the UK housebuilding and commercial sectors, announces a trading update ahead of its annual results for the financial year ended 30 September 2019, which will be announced on 10 December 2019.
The Board expects the Group’s profits for the full year ended 30 September 2019 to be in line with market expectations.
The Group’s divisional revenues have increased year-on-year: Tamdown will achieve high single-digit percentage revenue growth. TriConnex will deliver strong revenue growth following an overall increase in the number of projects secured and the acceleration of certain projects in the period; and eSmart Networks continues to successfully scale-up.
KEFI Minerals (KEFI) 0.72p £5.36m
KEFI Minerals, the gold exploration and development company with projects in the Federal Democratic Republic of Ethiopia and the Kingdom of Saudi Arabia, reports that following the commencement of drilling activities at the Company’s Hawiah Exploration Licence in Saudi Arabia, as announced on 30 September 2019, the first drill hole (HWD_001) has intercepted a 15.8 metre interval (true width estimated at 8 metres) of massive sulphide at a vertical depth of 125 metres. The mineralisation encountered presents dominantly as pyrite and chalcopyrite (a principal ore for copper), and minor bornite, with associated alteration and lithology consistent with that of a Volcanic Massive Sulphide “VMS” system.
ReNeuron Group (RENE) 146.5p £43.3m
ReNeuron Group, a UK-based global leader in the development of cell-based therapeutics, announced that new data relating to its CTX stem cell platform will be presented today at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), a leading scientific conference taking place this week in Barcelona, Spain.
Dr Steve Pells, Principal Investigator at ReNeuron, will present new data showing the phenotypic stability and scalability of a mesenchymal stem cell line derived from the Company’s proprietary, conditionally immortalised, human neural stem cell line (CTX) following re-programming to a pluripotent state.
Range Resources (RRL) 0.04p £2.76m
Range, an international company with oil and gas projects and oilfield service businesses in Trinidad and Indonesia, announced it has signed a Sale and Purchase Agreement with Wilson Energy Services Inc., a private company incorporated in Canada for the sale of four drilling rigs and related equipment for a total cash consideration of US$3.6 million.
easyHotel (EZH) 102p £148.9m
Further to the Company’s announcement in December 2018, planning permission for the development of the 209-room easyHotel Paris-Charles de Gaulle Airport has now been granted.
The Group has secured an operating lease agreement with Groupe ADP The hotel will be let on a 24-year FRI lease at an annual rent of approximately €1.1 million.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.